In the Claims

Please amend Claim 1 as follows.

1. (currently amended) An aqueous phase and oil phase composition comprising an amphoteric surfactant, a polypropoxylated cetyl alcohol and a polar drug selected from the group consisting of sodium cromoglycate and nedocromil sodium, said composition being adapted to provide transdermal transmission of said polar drug.

2. (previously cancelled).

3. (previously amended) A composition according to Claim 1 wherein the amphoteric surfactant is a balanced amphoteric surfactant.

4. (previously amended) A composition according to Claim 1, including ethoxylated cetyl alcohol.

5. (previously amended) A composition according to Claim 1 wherein the amphoteric surfactant comprises disodium cocoamphodiacetate.

6-8. (previously cancelled).

9. (previously amended) A composition according to Claim 1 wherein the composition further comprises a corticosteroid.

10. (previously cancelled).

11. (previously amended) A composition according to Claim 1 wherein the composition is an oil-in-water emulsion.

12. (previously amended) A composition according to Claim 1 wherein the composition is a foam.

13. (previously amended) A composition consisting essentially of:

sorbitan tristearate or non-ionic emulsifying wax 0.5 to 5% w/v

glycerol monostearate	0.5 to 5% w/v
light liquid paraffin	1 to 20% w/v
white soft paraffin	1 to 10% w/v
iso propyl myristate	0.5 to 5% w/v
polar drug	0.1 to 20% w/v
disodium edetate	0.01 to 1% w/v
amphoteric surfactant	0.1 to 10% w/v
alkoxylated cetyl alcohol	0.1 to 10% w/v
triclosan	0.01 to 1% w/v
benzyl alcohol	0.01 to 1% w/v
purified water	to 100% of the emulsion

14. (previously cancelled).

15. (previously amended) A method for topically delivering a pharmaceutical composition into a user's skin, comprising:

(a) providing a polar drug selected from the group consisting of sodium cromoglycate and nedocromil sodium; and

(b) applying said polar drug to the skin of the user in or with a formulation comprising alkoxylated cetyl alcohol and an amphoteric surfactant.

16. (previously cancelled)

17. (previously amended) A composition as in Claim 1 for treating a skin disease or skin condition selected from the group consisting of atopic dermatitis, contact sensitivity, psoriasis, drug sensitivity reactions, apthous ulcers, Behcet's syndrome, pemphigus, urticaria, urticaria pigmentosa, pyroderma gangrenosum, chronic skin ulcers, ulcers associated with Crohn's disease, burns, insect stings/bites, herpetic infections, systemic sclerosis, morphoea, dermal nodular fibrosis, and sunburn by applying said composition to the skin of an individual affected by the disease or condition.

18-20. (previously cancelled).

21. (previously amended) A method as in Claim 15 for the treatment of a skin disease or skin condition selected from the group consisting of atopic dermatitis, contact sensitivity, psoriasis, drug sensitivity reactions, apthous ulcers, Behcet's syndrome, pemphigus, urticaria, urticaria

pigmentosa, pyroderma gangrenosum, chronic skin ulcers, ulcers associated with Crohn's disease, burns, insect stings/bites, herpetic infections, systemic sclerosis, morphoea, dermal nodular fibrosis, and sunburn.

22. (previously amended) A method according to Claim 21 wherein the skin disease or condition is, has been or will be further treated by application of a corticosteroid.

23. (previously amended) A composition as in Claim 1 for treating patient in need of said polar drug by applying said composition to the skin of the patient.

24-27. (previously cancelled).

28. (previously amended) The composition of Claim 1 being packaged in a tube, tub, bottle or pressurised aerosol container.

29-30. (previously cancelled).

31. (previously added) A method as in Claim 15 wherein said alkoxylated cetyl alcohol is polypropoxylated cetyl alcohol.